HARVONI Drug Patent Profile

Which patents cover Harvoni, and what generic alternatives are available?

Harvoni is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are seventeen patents protecting this drug.

This drug has five hundred and sixty-five patent family members in fifty countries.

The generic ingredient in HARVONI is ledipasvir; sofosbuvir. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ledipasvir; sofosbuvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Harvoni

Harvoni was eligible for patent challenges on October 10, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 14, 2032. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for HARVONI

International Patents:	565
US Patents:	17
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	36
Drug Prices:	Drug price information for HARVONI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HARVONI
What excipients (inactive ingredients) are in HARVONI?	HARVONI excipients list
DailyMed Link:	HARVONI at DailyMed

See drug prices for HARVONI

See drug sales revenues for HARVONI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for HARVONI

NDA:

212477

Dosage:

PELLETS;ORAL

NDA:

205834

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for HARVONI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mansoura University	Phase 3
Cairo University	Phase 2/Phase 3
University of Maryland, College Park	Early Phase 1

See all HARVONI clinical trials

Pharmacology for HARVONI

Drug Class	Hepatitis C Virus NS5A Inhibitor Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors P-Glycoprotein Inhibitors RNA Replicase Inhibitors

US Patents and Regulatory Information for HARVONI

HARVONI is protected by seventeen US patents and four FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes					Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No					Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-002	Aug 28, 2019		RX	Yes	Yes					Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No					Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes					Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No					Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No					Y

International Patents for HARVONI

When does loss-of-exclusivity occur for HARVONI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Germany

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Moldova, Republic of

Montenegro

Morocco

New Zealand

Paraguay

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering HARVONI around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	729172
European Patent Office	2752422
Portugal	3309157
Australia	2012346217
Montenegro	03009
Spain	2758726
Costa Rica	20120534

Supplementary Protection Certificates for HARVONI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2430014	201640001	Slovenia		PRODUCT NAME: LEDIPASVIR; NATIONAL AUTHORISATION NUMBER: EU/1/14/958/001-002; DATE OF NATIONAL AUTHORISATION: 20141117; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2203462	122014000108	Germany		PRODUCT NAME: SOVALDI (SOFOSBUVIR); NAT. REGISTRATION NO/DATE: EU /1/13/894 20140116; FIRST REGISTRATION: EU EU/1/13/894 20140116
2430014	C20160002 00186	Estonia		PRODUCT NAME: LEDIPASVIIR;REG NO/DATE: EU/1/14/958 18.11.2014
2203462	SPC/GB14/078	United Kingdom		PRODUCT NAME: SOFOSBUVIR; REGISTERED: UK EU/1/13/894/001 20140117; UK EU/1/13/894/002 20140117
2203462	C 2014 043	Romania		PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894(001-002); DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/894(001-002); DATE OF FIRST AUTHORISATION IN EEA: 20140116
2203462	14C0082	France		PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2430014	631	Finland

Market Dynamics and Financial Trajectory for HARVONI

Last updated: February 19, 2026

What Are the Key Market Drivers for HARVONI?

HARVONI (ledipasvir and sofosbuvir) is a hepatitis C virus (HCV) antiviral drug approved by the U.S. Food and Drug Administration (FDA) in October 2014. Its market expansion is driven by several factors:

• High Cure Rates: HARVONI offers cure rates exceeding 95% in clinical settings, reducing the need for prolonged treatments.
• Patient Population: An estimated 71 million globally suffer from chronic HCV infection, with a significant portion in the United States, Europe, and emerging markets.
• Shift from Interferon-based Therapies: It replaced interferon-based regimens, which had lower efficacy and severe side effects.
• Pricing and Reimbursement: Initial high prices prompted negotiations and value-based pricing models, affecting market access.

How Has HARVONI's Market Share Evolved?

Harvoni quickly established dominance in the HCV treatment market:

• Market Penetration: Reported sales of $20 billion in 2015 and peaked at $21.1 billion in 2016 (Gilead Sciences Inc., 2016).
• Market Share: Secured approximately 80% of the HCV pharmaceutical market within two years of launch.
• Competitive Landscape: Faced competition from drugs including Sovaldi (sofosbuvir) and newer agents like Vosevi (sofosbuvir/velpatasvir/voxilaprevir).

What Are the Revenue Trends and Forecasts?

Gilead Sciences maintained high revenues from HARVONI with fluctuations influenced by patent expirations and market dynamics:

Year	Revenue (USD billion)	Growth Rate	Notable Factors
2014	N/A (launch year)	—	Launch; initial market penetration
2015	20.3	+30%	Rapid adoption; expanding indications
2016	21.1	+4%	Peak sales; increased market share
2017	16.2	-23%	Patent challenges; pricing pressures
2018	13.9	-14%	Competition from generics; emerging markets
2019	12.7	-9%	Saturation of available markets; treatment adherence issues

Forecast models project that HARVONI's revenue will decline gradually:

• 2023-2025: Estimated revenues forecasted to fall below $10 billion annually.
• Market Saturation: Many patients have been treated, limiting growth.
• Patent Expiry and Generics: By 2025, generic versions are expected in key markets such as India and Europe.

How Do Patent Expirations and Regulatory Changes Impact Defaults?

Gilead's patent on HARVONI expired or is set to expire in several jurisdictions, affecting revenue streams:

• United States: Patent expired in December 2023.
• Europe: Patent expiry anticipated in early 2024.
• India: Generic versions accessible since 2020 via compulsory licensing.

Market entry of generics reduces prices significantly, with discounts reaching 60-80%, impacting branded sales.

What Are the Competitive Responses?

Key competitors include:

• Vosevi (Gilead): Approved for retreatment; targets patients who failed initial therapies.
• Epclusa (Gilead): Broader genotype coverage.
• Sofosbuvir-based generics: Widely available in emerging markets at much lower prices.
• Innovative Agents: Companies like AbbVie and Merck develop drugs with shorter durations or broader indications.

How Do Policy and Reimbursement Strategies Affect Market Penetration?

Health policies influence the drug's adoption:

• Reimbursement: Countries with strict cost controls or limited healthcare budgets delay or restrict access.
• Pricing Negotiations: Gilead adjusted prices in some countries to improve access, affecting gross revenues.
• Disease Awareness: Programs increased screening, potentially expanding the eligible patient base.

What Are the Future Market Opportunities and Risks?

Potential growth avenues:

• Retreatment Market: Addressed by newer combination regimens.
• Combination with New Agents: Exploring HARVONI within multi-drug regimens for broader applications.
• Global Expansion: Focus on India, Africa, Southeast Asia.

Risks include:

• Patent Challenges: Legal disputes could shorten exclusivity.
• Pricing Pressures: Governments pushing for lower drug prices.
• Market Saturation: Declining untreated patient population.

Summary Table: Key Financial Metrics for HARVONI (2014–2022)

Year	Revenue (USD billion)	Key Events	Notes
2014	N/A	Launch
2015	20.3	Rapid growth
2016	21.1	Peak sales	Patent protections reinforced
2017	16.2	Patent challenges impact sales	Limited access in some regions
2018	13.9	Entry of generics in emerging markets	Price discounts impact revenues
2019	12.7	Market maturation	Competition intensifies
2020–2022	Declining trend	Market saturation, patent expiries	Focus on retreatment, combination regimens

Key Takeaways

• HARVONI achieved rapid market penetration post-launch due to high efficacy and improved treatment protocols.
• Revenue peaked in 2016, then declined due to patent expiration, generics, and market saturation.
• Growing competition from generics and regulatory pressures are pressurizing sales.
• Future revenue depends on global expansion, retreatment strategies, and innovations in combination therapies.
• Price competition and patent challenges will continue to influence its financial trajectory.

FAQs

1. What impacted HARVONI's revenue after its peak in 2016?
   Patent expirations, introduction of generic versions, and market saturation caused revenue declines post-2016.

2. When do key patents for HARVONI expire?
   Typically in late 2023 in the U.S. and early 2024 in Europe, leading to generic competition.

3. Are there regulatory barriers affecting HARVONI sales?
   Yes. Countries with strict price controls and limited healthcare budgets restrict access, influencing sales figures.

4. Which markets hold growth opportunities amidst declining revenues?
   Emerging markets such as India, Southeast Asia, and Africa present opportunities due to increasing hepatitis C prevalence and affordability measures.

5. How are competitors impacting HARVONI's market position?
   Generic formulations and newer combination drugs targeting resistant or retreatment patient populations challenge HARVONI’s foothold.

---

References

[1] Gilead Sciences Inc. (2016). Annual report.
[2] U.S. Food and Drug Administration (2014). HARVONI approval letter.
[3] World Health Organization. (2020). Global hepatitis report.